Vinva Investment Management Reduces IDEXX Laboratories Stake

Institutional investor sells over 22,000 shares of the veterinary diagnostics company

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd. reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 74.4% in the 3rd quarter, according to a recent SEC filing. The fund now owns 7,617 shares of the company's stock after selling 22,172 shares during the period.

Why it matters

IDEXX Laboratories is a leading provider of diagnostic products and services for the animal health, water testing, and food safety markets. The company's stock has seen significant growth in recent years, making it an attractive investment for institutional investors like Vinva. This reduction in Vinva's stake could signal a shift in the firm's investment strategy or portfolio allocation.

The details

According to the filing, Vinva Investment Management's holdings in IDEXX Laboratories were valued at $4.8 million as of the most recent reporting period. The firm sold 22,172 shares of the company's stock during the 3rd quarter. IDEXX Laboratories' stock price has fluctuated in recent months, trading between a 52-week low of $356.14 and a high of $769.98.

  • Vinva Investment Management reduced its IDEXX Laboratories stake in the 3rd quarter of 2026.

The players

Vinva Investment Management Ltd

An institutional investment firm that reduced its position in IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

A global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Vinva Investment Management's IDEXX Laboratories stake could signal a shift in the firm's investment strategy or portfolio allocation, though the reasons behind the move are not entirely clear. IDEXX Laboratories remains an important player in the veterinary diagnostics market, and its stock performance will likely continue to be closely watched by investors.